Consumer Law

[Name of the Writer]

[Name of the Institution]

Consumer Law

Consumer rights are emphasized hugely all over the world. The courts, especially the consumer courts, all over the world, strive to protect the rights of the consumers and provide justice to them wherever there is injustice being done to the end consumer. American Consumer Courts perform the same function, every day. They have always been striving to protect the rights of the consumers on a large basis. The cases are being dealt on the foundations of Administrative and Federal grounds. One of the instances of such cases is the “Impax Laboratories, Inc., In the Matter of”. The details of this case have been provided as under.

**Summary**

The case actually started in 2017, when Impax Pharmaceuticals Inc. sued Endo Pharmaceuticals Pvt Ltd for marketing its drugs without getting it patented in the market. Patients are usually ready to pay extra for prescription drugs. Under consumer law, it's not allowed by the generic companies to produce or market drugs under the generic name.

Endo Pharmaceuticals was working as an anti-competitive drug retailer in the market. It initially got permission to market the drugs under its brand. The court of consumer market regarded this case as an issue of “reverse payment”.

**Legal Conclusion**

 **The** American consumer court gave the best ruling over the case, as it could be. Any judge who would have been proceeding the case would have given the same ruling or verdict over the case (Impax Laboratories, Inc., In the Matter of, 2017). If I would have been proceedings over the legal procedures of this case I would have also given the same ruling, i.e., to repay the losses incurred to the actual manufacturer of the drug. In addition to that, I would put a ban on the production of generic drugs by Endo Pharmaceuticals Pvt Ltd.

Further details of this case can be found at <https://www.ftc.gov/enforcement/cases-proceedings/141-0004/impax-laboratories-inc>.

**References**

Impax Laboratories, Inc., In the Matter of, 141 0004 (Federal Trade Commission January 23, 2017). Retrieved from https://www.ftc.gov/system/files/documents/cases/d09373\_impax\_laboratories\_opinion\_of\_the\_commission\_-\_public\_redacted\_version\_redacted\_0.pdf